# Study on the Safety and Efficacy of PA9159 Inhalation Aerosol for the Treatment of Adult Bronchial Asthma

> **NCT07324707** · PHASE2 · RECRUITING · sponsor: **Anhui Palo Alto Pharmaceuticals, Inc.** · enrollment: 30 (estimated)

## Conditions studied

- Bronchial Asthma

## Interventions

- **DRUG:** PA9159 Metered-Dose Inhaler, 120 μg per day for 28 days
- **DRUG:** Fluticasone Propionate Inhaled Aerosol 200 μg per day for 28 days

## Key facts

- **NCT ID:** NCT07324707
- **Lead sponsor:** Anhui Palo Alto Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-10-15
- **Primary completion:** 2026-03
- **Final completion:** 2026-03
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-01-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07324707

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07324707, "Study on the Safety and Efficacy of PA9159 Inhalation Aerosol for the Treatment of Adult Bronchial Asthma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07324707. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*